Department of Translational Biology, GlaxoSmithKline, Neuroscience Centre of Excellence for Drug Discovery, Verona, Italy.
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5044-9. doi: 10.1016/j.bmcl.2010.07.037. Epub 2010 Jul 14.
Novel series of pyrrole-pyrazinone and pyrazole-pyrazinone have been identified as potent and selective Vasopressin(1b) receptor antagonists. Exploration of the substitution pattern around the core of these templates allowed generation of compounds with high inhibitory potency at the Vasopressin(1b) receptor, including examples that showed good selectivity with respect to Vasopressin(1a), Vasopressin(2), and Oxytocin receptor subtypes.
新型吡咯-哒嗪酮和吡唑-哒嗪酮系列化合物已被鉴定为强效和选择性的血管加压素(1b)受体拮抗剂。对这些模板核心周围取代模式的探索允许生成在血管加压素(1b)受体上具有高抑制效力的化合物,包括显示出对血管加压素(1a)、血管加压素(2)和催产素受体亚型具有良好选择性的实例。